Palvella Financial Statements From 2010 to 2026

PVLA Stock   86.98  1.68  1.97%   
Palvella Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Palvella Therapeutics' valuation are provided below:
Market Capitalization
B
Earnings Share
(2.92)
We have found ninety-four available trending fundamental ratios for Palvella Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Palvella Therapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Palvella Therapeutics Total Revenue

0.0

Check Palvella Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Palvella Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.4 M, Interest Expense of 5.2 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.42, Dividend Yield of 0.0 or PTB Ratio of 0.52. Palvella financial statements analysis is a perfect complement when working with Palvella Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Palvella Stock
Check out the analysis of Palvella Therapeutics Correlation against competitors.
For information on how to trade Palvella Stock refer to our How to Trade Palvella Stock guide.

Palvella Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding2.7 M2.6 M910.3 K
Slightly volatile
Total Assets59.3 M79.4 M91.7 M
Slightly volatile
Short and Long Term Debt Total13 M13.7 M19.5 M
Pretty Stable
Other Current Liabilities5.4 M6.7 M6.7 M
Very volatile
Total Current Liabilities14.9 M10.8 M20 M
Slightly volatile
Property Plant And Equipment Net19.6 M20.7 M24.6 M
Slightly volatile
Current Deferred Revenue20.8 M28.9 M17 M
Slightly volatile
Accounts Payable3.1 M4.1 M2.6 M
Slightly volatile
Cash47.2 M75.2 M66 M
Pretty Stable
Non Currrent Assets Other26.6 M25.4 M9.3 M
Slightly volatile
Cash And Short Term Investments47.2 M75.2 M66 M
Pretty Stable
Liabilities And Stockholders Equity59.3 M79.4 M91.7 M
Slightly volatile
Non Current Liabilities Total11.6 M12.2 M41.3 M
Slightly volatile
Other Current Assets2.1 M2.1 M3.1 M
Slightly volatile
Other Stockholder Equity113.4 M140.7 M199.4 M
Slightly volatile
Total Liabilities40.6 M23.1 M62.2 M
Slightly volatile
Total Current Assets50.5 M79.4 M70.8 M
Pretty Stable
Short Term Debt783.5 K773.1 K971.3 K
Slightly volatile
Common Stock9.4 K9.9 K47.3 K
Slightly volatile
Short Term Investments16.4 M18.5 M20.2 M
Slightly volatile
Capital Stock9.4 K9.9 K58.1 M
Slightly volatile
Non Current Liabilities Other14 M10.7 M27.4 M
Slightly volatile
Net Working Capital92 M87.6 M23.6 M
Slightly volatile

Palvella Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.4 M3.2 M1.4 M
Slightly volatile
Other Operating Expenses15.4 M16.2 M32.4 M
Slightly volatile
Research Development8.9 M9.4 M22.4 M
Pretty Stable
Total Operating Expenses15.4 M16.2 M31.7 M
Slightly volatile
Gross Profit21.7 M20.8 M27.3 M
Slightly volatile
Cost Of Revenue2.8 M3.2 M2.5 M
Slightly volatile
Selling General Administrative4.8 M6.8 M4.4 M
Slightly volatile
Selling And Marketing Expenses9.8 M11 M12 M
Slightly volatile
Interest IncomeM5.6 M6.2 M
Slightly volatile

Palvella Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow6.3 M6.6 M47.8 M
Slightly volatile
Depreciation2.5 M2.7 M2.2 M
Slightly volatile
Total Cash From Financing Activities105.2 M100.2 M28.1 M
Slightly volatile
End Period Cash Flow47.2 M75.2 M66 M
Pretty Stable
Stock Based Compensation682 K954.5 K507.1 K
Slightly volatile
Other Cashflows From Financing Activities6.2 M7.8 M8.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.420.550.473
Slightly volatile
Days Sales Outstanding30.7934.6437.8096
Slightly volatile
Stock Based Compensation To Revenue0.01320.01480.0162
Slightly volatile
Capex To Depreciation0.440.460.9765
Slightly volatile
Payables Turnover0.460.790.4219
Slightly volatile
Research And Ddevelopement To Revenue2.192.232.0444
Pretty Stable
Capex To Revenue0.02420.02720.0297
Slightly volatile
Cash Per Share56.843.19112
Slightly volatile
Days Payables Outstanding9604801.1 K
Slightly volatile
Current Ratio6.936.63.9443
Slightly volatile
Receivables Turnover7.588.539.3152
Slightly volatile
Debt To Equity0.460.340.4698
Slightly volatile
Capex Per Share0.941.061.1555
Slightly volatile
Revenue Per Share36.7332.0236.4441
Slightly volatile
Interest Debt Per Share2.122.2313.625
Slightly volatile
Debt To Assets0.140.110.142
Slightly volatile
Enterprise Value Over EBITDA4.13.92.222
Slightly volatile
Operating Cycle30.7934.6437.8096
Slightly volatile
Days Of Payables Outstanding9604801.1 K
Slightly volatile
Total Debt To Capitalization0.320.260.3162
Slightly volatile
Debt Equity Ratio0.460.340.4698
Slightly volatile
Quick Ratio6.936.63.9443
Slightly volatile
Cash Ratio6.566.253.7037
Slightly volatile
Days Of Sales Outstanding30.7934.6437.8096
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.871.011.0605
Pretty Stable
Fixed Asset Turnover1.091.231.3401
Slightly volatile
Enterprise Value Multiple4.13.92.222
Slightly volatile
Debt Ratio0.140.110.142
Slightly volatile
Price Sales Ratio0.420.550.473
Slightly volatile
Asset Turnover0.711.410.5458
Slightly volatile
Gross Profit Margin1.01.030.9296
Slightly volatile

Palvella Fundamental Market Drivers

About Palvella Therapeutics Financial Statements

Palvella Therapeutics stakeholders use historical fundamental indicators, such as Palvella Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Palvella Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Palvella Therapeutics' assets and liabilities are reflected in the revenues and expenses on Palvella Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Palvella Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue28.9 M20.8 M
Cost Of Revenue3.2 M2.8 M
Stock Based Compensation To Revenue 0.01  0.01 
Research And Ddevelopement To Revenue 2.23  2.19 
Capex To Revenue 0.03  0.02 
Revenue Per Share 32.02  36.73 
Ebit Per Revenue(1.93)(2.03)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Palvella Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palvella Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palvella Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palvella Therapeutics Stock:
Check out the analysis of Palvella Therapeutics Correlation against competitors.
For information on how to trade Palvella Stock refer to our How to Trade Palvella Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palvella Therapeutics. If investors know Palvella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palvella Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.92)
Return On Assets
(0.48)
Return On Equity
(3.01)
The market value of Palvella Therapeutics is measured differently than its book value, which is the value of Palvella that is recorded on the company's balance sheet. Investors also form their own opinion of Palvella Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Palvella Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palvella Therapeutics' market value can be influenced by many factors that don't directly affect Palvella Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palvella Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Palvella Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palvella Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.